↓ Skip to main content

Dove Medical Press

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Overview of attention for article published in Drug Design, Development and Therapy, July 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

wikipedia
2 Wikipedia pages

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
37 Mendeley
Title
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
Published in
Drug Design, Development and Therapy, July 2019
DOI 10.2147/dddt.s172512
Pubmed ID
Authors

Thomas G Cotter, Donald M Jensen

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 37 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 19%
Student > Master 6 16%
Researcher 5 14%
Student > Ph. D. Student 3 8%
Student > Postgraduate 2 5%
Other 1 3%
Unknown 13 35%
Readers by discipline Count As %
Medicine and Dentistry 12 32%
Biochemistry, Genetics and Molecular Biology 4 11%
Chemistry 2 5%
Linguistics 1 3%
Immunology and Microbiology 1 3%
Other 3 8%
Unknown 14 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2021.
All research outputs
#8,648,703
of 25,658,541 outputs
Outputs from Drug Design, Development and Therapy
#656
of 2,276 outputs
Outputs of similar age
#145,613
of 364,694 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 41 outputs
Altmetric has tracked 25,658,541 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,276 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,694 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.